Ключевые слова:
множественная миелома, плазмоцитома, молекулярная генетика, полиморфизм, интерлейкин 17А.Библиографические ссылки
Менделеева Л.П., Вотякова О.М., Рехтина И.Г., и др. Множественная миелома. Клинические рекомендации. Современная Онкология. 2020; 22(4): 6–28
Curado MP, Oliveira MM, Silva DRM and Souza DLB: Epidemiology of multiple myeloma in 17 Latin American countries: An update. Cancer Med. 7:2101–2108. 2018;
Sun H. et al. Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma //Journal for immunotherapy of cancer. – 2021. – Т. 9. – №. 7.
Shahzad M. N. et al. Association between interleukin gene polymorphisms and multiple myeloma susceptibility //Molecular and Clinical Oncology. – 2020. – Т. 12. – №. 3. – С. 212–224.;
T V, V G and A ND: Multiple myeloma index for risk of infection. J Cancer. 9:2211–2214. 2018.
Soekojo CY, de Mel S, Ooi M, Yan B and Chng WJ: Potential clinical application of genomics in multiple myeloma. Int J Mol Sci. 9(pii: E1721)2018;
Jupe S, Ray K, Roca CD, Varusai T, Shamovsky V, Stein L, D'Eustachio P and Hermjakob H: Interleukins and their signaling pathways in the Reactome biological pathway database. J Allergy Clin Immunol. 141:1411–1416. 2018.
Allegra A. et al. Lymphocyte subsets and inflammatory cytokines of monoclonal gammopathy of undetermined significance and multiple myeloma //International Journal of Molecular Sciences. – 2019. – Т. 20. – №. 11. – С. 2822.
Musolino C. et al. Inflammatory and anti–inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma //Mediators of inflammation. – 2017. – Т. 2017;
Nazarova E. L. et al. Molecular features of bortezomib–induced neuropathy in patients with multiple myeloma //Russian journal of hematology and transfusiology. – 2019.– Т. 64. – №. 1. – С. 79–89.
Nazarova E. L. et al. Prognostic Value of Genetic Markers for Efficacy Estimation of Induction Treatment Including Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients. – 2018.;
Serin I. et al. Effect of interleukin–2 (IL–2) polymorphisms on multiple myeloma: IL–2RA rs2104286, IL–2 rs2069762 and rs2069763 polymorphisms // Cytokine. – 2023. – Т. 172. – С. 156401].
Svitina S. P. et al. Polymorphism of Interleukins and Tumor Necrosis Factor α Genes in Multiple Myeloma Patients with Autologous Hematopoietic Stem Cell Transplantation. – 2021.;
Szudy–Szczyrek A. et al. Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first–line CTD therapy in multiple myeloma patients //Oncotarget. – 2018. – Т. 9. – №. 35. – С. 24054.
Бессмельцев С.С. Множественная мие-лома: диагностика и терапия (часть 2). Вестник гематологии. 2022;18(3):4–31 [Bessmeltsev SS. Multiple myeloma: diagnosis and therapy (part 2). Bulletin of Hematology. 2022;18(3):4–31 (in Russian)].